Our results demonstrated that while the single agents targeting either PD1 (HX008) or CD47 (SIRPα) have anti-tumor activity, as shown in Fig. 3C, the dual targeting by HX009 induced a synergistic anti-tumor activity, as shown in Fig. 3C. These data, in this complex model system that leverages the need for host innate immunity, strongly supports the notion of enhanced treatment benefit through the dual targeting of both CD47 and PD1. Here, SIRPA is linked to neoplasm.